Argenx Se, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Derek Archila from Wells Fargo maintained a Buy rating on the stock and has a $741.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Derek Archila has given his Buy rating due to a combination of factors including Argenx Se’s impressive financial performance in the second quarter of 2025. The company’s Vyvgart revenues significantly exceeded expectations, reaching $949 million compared to the anticipated $863 million to $880 million. This strong performance suggests that Argenx’s growth trajectory remains solid, alleviating previous concerns about pricing and growth.
Furthermore, the management’s insights into the number of patients on therapy and the pricing strategy indicate a positive outlook. The number of CIDP patients was in line with projections, and the pricing came in better than expected, which is a favorable sign for the company’s financial health. Additionally, the anticipated continuation of robust growth in the latter half of 2025, supported by potential increases in patient growth and utilization, reinforces the Buy rating.